Programming - BCVS Scientific Sessions 2022

About this Meeting

The 16th annual BCVS 2022 Scientific Sessions has become the premier conference for molecular cardiovascular biology and disease. Sponsored by the American Heart Association Basic Cardiovascular Sciences Council, the world’s leading organization of cardiovascular scientists, the conference attracts leading researchers in fields such as microRNAs, cardiac gene and cell therapy, cardiac development and most recently tissue engineering and iPS cells.

BCVS 2022 Final Program

Monday, July 25

Monday July 25
TIME (Central Time) ACTIVITY 
8:00 a.m. – 8:45a.m AHA Research Overview
Glenn Dillon, PhD | American Heart Association
9:00 a.m. – 9:15 a.m. Early Career Opening Remarks
Susmita Sahoo, PhD | Mount Sinai School of Medicine
Sarah Schumacher-Bass, PhD | Cleveland Clinic
9:15 a.m. – 10:15 a.m.

Early Career Session 1: Next Best Thing in Cardiovascular Research
Moderators:
Dominic P. Del Re, PhD, Rutgers University
Kedryn K. Baskin, PhD, Ohio State University

  • Premature Stop Mutations In Mybphl Share The Common Pathomechanism Of Preventing Protein Incorporation Into The Cardiac Myofilament
    Alejandro Alvarez-Arce, Kelly Araujo, Lucas Wittenkeller, David Y Barefield, Loyola Univ Chicago, Maywood, IL
  • RBPMS, An RNA-binding Protein That Mediates Cardiomyocyte Binucleation And Cardiovascular Development
    Peiheng Gan, UT Southwestern Medical Ctr, Dallas, TX; Rhonda S Bassel-Duby, UT SOUTHWESTERN MEDICAL CENTER, Plano, TX; Ning Liu, UT Southwestern Medical Ctr, Dallas, TX; Eric N Olson, UNIV TEXAS SOUTHWESTERN MED CTR, Dallas, TX
  • A Novel Nuclear Role For REDD1 In Cardiac Insulin Sensitivity And Resistance
    Mason Wheeler, Fralin Biomedical Res Inst at Virginia Tech, Roanoke, VA; jessica Ibetti, Walter J Koch, TEMPLE UNIVERSITY SCHOOL MEDIC, Philadelphia, PA; Jessica M Pfleger, Virginia Tech Carilion, Philadelphia, PA
10:15 a.m. – 10:45 a.m. Break/Exhibits
10:45 a.m. – 11:45 a.m.

Early Career Session 2: Next Best Thing in Cardiovascular Research
Moderators: 
Patricia Nguyen, MD, Stanford University
Mohammad Al-Khalaf, PhD, Ottawa Heart Institute

  • Mitochondrial Microdomain Disruption Results In Sinus Node Dysfunction In Heart Failure
    Lu Ren, Stanford Univ, Palo Alto, CA; Raghavender Reddy Gopireddy, UC Davis, Davis, CA; Guy Perkins, UCSD, San Diego, CA; Valeriy Timofeyev, Yankun Lyu, Daphne A Diloretto, James Overton, Wilson Xu, Nathan Grainger, Elena N Dedkova, Xiao-Dong Zhang, UC Davis, Davis, CA; Ebenezer Yamoah, Univ of Nevada, Reno, Reno, NV; Manuel F Navedo, Nipavan Chiamvimonvat, Phung N Thai, UC Davis, Davis, CA
  • A Mouse Model Carrying The R502W Mutation In Cardiac Myosin Binding Protein C (cMyBP-C) Leads To Hypertrophic Myocardial Remodeling In The Absence Of <cMyBP-C> Haploinsufficiency
    Laura Sen-Martín, Ángel Fernández-Trasancos, Miguel Lopez-Unzu, David Sánchez-Ortiz, María Rosaria Pricolo, Jorge Alegre-Cebollada, Ctr Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
  • Cardiac Fibroblast GSK-3α Aggravates Ischemic Cardiac Injury By Promoting Fibrosis, Inflammation, And Impairing Angiogenesis
    Prachi Umbarkar, Sultan Tousif, Suma Ejantkar, Angelica Toro Cora, Qinkun Zhang, Hind Lal, Univ of Alabama at Birmingham, Birmingham, AL
11:45 a.m. – 12:30 p.m. Early Career Keynote Address
Ivor Benjamin, MD, FACC, FAHA | Medical College of Wisconsin
Moderator: Sean Wu, MD, PhD, Stanford University
12:30 p.m. – 1:00 p.m. Break/Exhibits
1:00 p.m. – 1:30 p.m.

Opening Welcome
Moderator:
Elizabeth McNally, MD, PhD, Northwestern University

Opening Remarks from the President of the American Heart Association
Michelle A. Albert, MD, University of California-San Francisco

Welcome Remarks from the BCVS Leadership Committee Chair
Jianyi “Jay” Zhang, MD, PhD, University of Alabama at Birmingham

1:30 p.m. – 2:45 p.m.

Session 1: Genetic Basis of Cardiomyopathy
Moderators:
Konstantinos Drosatos, MSc, PhD, University of Cincinnati
Brett A Colson, PhD, University of Arizona

  • Molecular substrates for sudden cardiac death in young athletes with Plakophilin-2 deficiency
    Mario Delmar, MD, NYU Langone Medical Center
  • Role of junctophilin in cardiomyopathies
    Xander Wehrens, MD, PhD, Baylor College of Medicine, Cardiovascular Research Institute
  • Insights into hypertrophic and dilated cardiomyopathy phenotypes studied in transgenic MYL2 mice
    Danuta Szczesna-Cordary, PhD, University of Miami
  • Myosin Binding Protein H-like Competes With Cardiac Myosin Binding Protein-c To Prolong Atrial Contraction
    Kelly Araujo, Loyola Univ Chicago, Maywood, IL; Kc Woulfe, UNIVERSITY OF COLORADO, Aurora, CO;
    Lucas Wittenkeller, David Y Barefield, Loyola Univ Chicago, Maywood, IL
2:45 p.m. – 3:15 p.m. Break/Exhibits
3:15 p.m. – 4:30 p.m.

Session 2: Cardiac Repair, Cellular Reprogramming and Tissue Engineering
Moderators:
Richard Lee, MD, Harvard University
Olaf Bergmann, PhD, Karolinska

  • Metabolic Regulation of Mammalian Heart Regeneration
    Ahmed Mahmoud, PhD, University of Wisconsin-Madison
  • Recent Advance in Direct Cardiac Reprogramming
    Li Qian, PhD, University of North Carolina
  • Prolonged Regenerative Capacity in the Neonatal Opossum Heart
    Wataru Kimura, PhD, Riken Center for Developmental Biology
  • Injection Of Human IPSC-derived Cardiac Cells Promote Cardiac Repair After Infarction In Nonhuman Primates
    Yu-Che Cheng, Inst of Biomedical Sciences, Academia Sinica, Taipei, Taiwan; Marvin Hsieh, Univ of Wisconsin-Madison, Madison, WI; Chen-Ju Lin, Univ of Wisconsin-Madison, Madison, WI, Taipei City; Cindy Miaochuan Chang, NCKU Res and Development Found, Tainan; Ching-Ying Huang, Riley Puntney, NCKU Res and Development Found, Tainan, New Taipei City; Amy Moy, Univ of WisconsinMadison, Madison, WI; Ting Chien-Yu, Darien Chan, Inst of Biomedical Sciences, Academia Sinica, Taipei, Taiwan; Martin Nicholson, Taipei; Jen-Hao Lin, Po-Ju Lin, Inst of Biomedical Sciences, Academia Sinica, Taipei, Taiwan; Hung-Chih Chen, Academia Sinica, Taipei; Gina Kim, Univ of WisconsinMadison, Madison, Madison, WI; Jennifer Coonen, Univ of Wisconsin-Madison, Madison, Madison, WI, Madison, WI; Yen-Wen Liu, DIVISION OF CARDIOLOGY, Tainan; Timothy A Hacker, Univ of Wisconsin, Madison, WI; Timothy Kamp, U OF WISCONSIN-MADISON, Madison, WI; Patrick C Hsieh, ACADEMIA SINICA, Taipei City
4:30 p.m. – 7:00 p.m. Poster Session 1 (Includes Poster Competition)

Tuesday, July 26

Tuesday Schedule
TIME (Central Time) ACTIVITY
7:00 a.m. – 8:00 a.m. Continental Breakfast
7:00 a.m. – 8:00 a.m.

Women in Science Breakfast
Moderators:
Nicole Purcell, PhD, Huntington Medical Research Institutes
Sarah Schumacher-Bass, PhD, Cleveland Clinic


BCVS Champions the Women and Embracing Diversity

  • Jane Freedman, MD, Vanderbilt University
    Editor-in-Chief, Circulation Research
  • Elizabeth McNally, MD, PhD, Northwestern University
    Editor-in-Chief, Journal of Clinical Investigation
  • Nancy Sweitzer, MD, PhD, University of Arizona Health Sciences
    Editor-in-Chief, Circulation Heart Failure
  • Rong Tian, MD, PhD, University of Washington
    Editor-in-Chief, Journal of Molecular and Cellular Cardiology
8:00 a.m. – 9:15 a.m.

Session 3: Small RNAs, Exosomes and Extracellular Vesicles in Cardiovascular Disease
Moderators:
Jiang Chang, MD, PhD, Texas A&M University
Susmita Sahoo, PhD, Mount Sinai

  • Interorgan Transport of Adipocyte Mitochondrial-derived Vesicles Precondition the Heart Against Ischemia Reperfusion Injury
    Clair Crewe, PhD, Washington University School of Medicine in St Louis
  • Cyclin D2 Overexpression Enhances the Efficacy of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes for Myocardial Repair in a Swine Model of Myocardial Infarction
    Jianyi “Jay” Zhang, MD, PhD, University of Alabama at Birmingham
  • Cardiac Extracellular Vesicles Accelerate Pathology of Diseases
    Jonathan Leor, MD, PhD, Tel Aviv University, Israel
  • Extracellular Vesicles Function As An Alternative Disposal Pathway For Mitochondria In The Heart
    Wenjing Liang, UNIVERSITY OF CALIFORNIA SAN DIEGO, San Diego, CA; Rachel Diao, UC San Diego, San Diego, CA; Rita Najor, Justin Quiles, Liguo Chi, UNIVERSITY OF CALIFORNIA SAN DIEGO, San Diego, CA; Asa Gustafsson, Univ of California, San Diego, La Jolla, CA
9:15 a.m. – 9:45 a.m. Refreshment Break/Exhibits
9:45 a.m. – 11:00 a.m.

Session 4: Advances in Cardiac Hypertrophy and Remodeling
Moderators:
Priscila Sato, PhD, Drexel University
Jiandong Liu, PhD, University of North Carolina

  • PKG1 blood pressure-independent anti-remodeling mechanisms
    Robert Blanton, MD, Tufts Medical Center
  • Secretion of Mitochondria as a Mitochondrial Quality Control Mechanism
    Asa Gustafsson, PhD, University of California San Diego
  • Regulation of post-transcriptional gene expression modulates myofibroblast activation 
    Michael Tranter, PhD, University of Cincinnati
  • Stress-induced Uhrf1 Epigenetically Modulates Angiogenesis And Cardiac Function In Ventricular Hypertrophy
    Arianna Felicetta, Humanitas Univ, Pieve Emanuele (Milan), Italy; Pierluigi Carullo, Humanitas Res Hosp, Rozzano (Milan), Italy; Giada Cassanmagnago, Humanitas Univ, Pieve Emanuele (Milan), Italy; Marco Cremonesi, Humanitas Res Hosp, Rozzano (Milan), Italy; Mauro Passaretti, Humanitas Univ, Pieve Emanuele (Milan), Italy; Federico Colombo, Javier Cibella, Gianluca Basso, Clelia Peano, Humanitas Res Hosp, Rozzano (Milan), Italy; Gianluigi Condorelli, Humanitas Res Hosp, Rozzano (Milan), Italy
11:00 a.m. - Noon

Session 5: Keynote Lecture
Moderators:
Pilar Alcaide, PhD, Tufts University
Sumanth Prabhu, MD, Washington University School of Medicine in St. Louis

  • From Bench to Bedside: The Role of Science in Treating a Deadly Disease
    Leslie Leinwand, PhD, University of Colorado
Noon – 1:30 p.m. Lunch on Your Own/Poster Viewing/Exhibits
Or
BCVS Early Career: Lunch with Legends
* Ticketed event for Early Career members to meet invited senior investigators.

Table Leaders: 
Sean Wu, MD PhD, Stanford University
Sakthi Sadayappan, PhD, University of Cincinnati
Jill Tardiff, PhD, University of Arizona
Susmita Sahoo, PhD, Mount Sinai
Åsa Gustafsson, PhD, UC San Diego
Steve Jones, PhD, University of Louisville
Sarah Schumacher, PhD, Cleveland Clinic
Elizabeth McNally, MD, PhD, Northwestern University
Jonathan Kirk, PhD, Loyola University Chicago
Rong Tian, PhD, University of Washington
Xinliang Ma, PhD, Thomas Jefferson University2
Young-sup Yoon, MD, PhD, Emory University
Nicole Purcell, PhD, Huntington Medical Research Institutes
Robin Shaw, MD, PhD, University of Utah
1:30 p.m. – 2:45 p.m.

Session 6: Hot Topics in Cardiac Fibrosis
Moderators:
Steven Jones, PhD, University of Louisville
Tariq Hamid, PhD, Washington University of St Louis

  • Cardiac fibroblast activity enables cardiomyocyte hypertrophy in vivo
    Jeff Molkentin, PhD, Cincinnati Children’s Hospital Medical Center
  • Targeting Fibroblast Subpopulations in Hypertensive Heart Disease
    Taben Hale, PhD, University of Arizona
  • Phenotypic Screening, Artificial Intelligence and New Therapeutic Targets for Cardiac Fibrosis
    Timothy McKinsey, PhD, University of Colorado Denver
  • Asporin, An Extracellular Matrix Protein, Is A Beneficial Regulator Of Cardiac Remodeling
    Deepika Rai, Cedars Sinai Medical Ctr, Los Angeles, CA; Chengqun Huang, Cedars-Sinai Medical Ctr, Los Angelos, CA; Reetu Thakur, Cedars Sinai Medical Ctr, Los Angeles, CA; Ankush Sharma, Univ of Oslo, Oslo, Norway; Roberta A Gottlieb, CEDARS-SINAI MEDICAL CENTER, Los Angeles, CA; Honit Piplani, Cedars Sinai Medical Ctr, Los Angeles, CA
2:45 p.m. – 3:15 p.m. Refreshment Break/Exhibits
3:15 p.m. – 4:30 p.m.

Session 7: Bench to Bedside: Cardiovascular Therapeutics not Lost in Translation
Moderators:
Farah Sheikh, PhD, University of California San Diego
Irene Cal Y Mayor-Turnbull, MD, Mount Sinai

  • Gene Therapy Approaches to Signal Cardiomyocyte Renewal in the Injured Heart
    James F. Martin, MD, Baylor College of Medicine
  • Variant effect mapping for inherited cardiomyopathy
    Victoria N. Parikh, MD, Stanford University School of Medicine
  • Fueling the Flames of Inflammation and Atherosclerosis: Role of Cell Death
    Katey Rayner, PhD, University of Ottawa Heart Institute
  • Nil10: A Newly Synthesized Nanoparticle That Reduces Inflammation And Preserves Heart Function In Murine And Porcine Models Of Acute Myocardial Infarction
    Laura Tesoro, Univ Francisco de Vitoria, Pozuelo De Alarcon, Spain; Laura Botana, Madrid; Ignacio Hernandez Navarro, Univ Francisco de Vitoria, Pozuelo de Alarcon, Spain; Rafael Ramirez-Carracedo, Univ Francisco de Vitoria, Pozuelo de Alarcon, Spain, Las Rozas; Jose L Zamorano, Hosp Ramon y Cajal, Madrid, Spain; Marta Saura, Univ de Alcala, Alcala De Henares, Spain; Carlos Zaragoza, Univ Francisco de Vitoria, Pozuelo De Alarcon
4:30 p.m. – 7:00 p.m. Poster Session 2 (Includes Poster Competition)
7:00 p.m. Early Career Social

Wednesday, July 27

Wednesday schedule
TIME (Central Time) ACTIVITY
7:00 a.m. – 8:00 a.m. Continental Breakfast/Registration/Exhibits
8:00 a.m. – 9:15 a.m.

Session 8: Novel Mechanisms of HFpEF and HFrEF
Moderators:
Edward Thorp, PhD, Northwestern University
Flora Sam, MD, Boston University

  • Mitochondrial Mechanisms in Heart Failure
    Rong Tian, MD, University of Washington
  • Lipid-based signaling in cardiometabolic HFpEF
    Gabriele Schiattarella, MD, Charite University MDC Berlin
  • Troponin I Tyrosine-26 Phosphorylation Improves Relaxation And Is Beneficial During Pathological Diastolic Dysfunction
    Lorien Salyer, Sarah Sturgill, Elizabeth Brundage, Hussam Salhi, Vikram Shettigar, Eaman Abay, Mark T Ziolo, Brandon Biesiadecki, The Ohio State Univ, Columbus, OH
9:15 a.m. – 9:45 a.m. Refreshment Break/Exhibits
9:45 a.m. – 11:00 a.m.

Session 9: The Heart and Cancer: New Insight
Moderators:
Douglas Sawyer, MD, Maine Health
Han Zhu, MD, Stanford University

  • Inter-organ cross-talk in anthracycline cardiomyopathy
    Aarti Asnani, MD, Beth Israel Deaconess
  • Metabolism through a Hyperpolarized Lens: from Hype to Breakthroughs
    Vlad Zaha, MD, UT Southwestern Medical Center
  • Acute and Chronic Cardiovascular Complications of Immune Checkpoint Inhibitors, Challenges and Insights into Cardiovascular Biology
    Tomas Neilan, MD, Massachusetts General Hospital
  • Ponatinib-induced Cardiotoxicity Is Driven By S100A8/A9-NLRP3-IL1β Signaling Mediated Excessive Inflammation
    Tousif Sultan, UAB, Birmingham, AL; Anand P Singh, Massachusetts General Hosp, Boston, MA; Prachi Umbarkar, UAB Sch of Med, Birmingham, AL; Cristi Galindo, Nicholas Wheeler, Western Kentucky Univ, Bowling Green, KY; qinkun zhang, Univ of Alabama at Birmingham, Birmingham, AL; Sumanth D Prabhu, Washington Univ, Saint Louis, MO; Hind Lal, UAB, Birmingham, AL
11:00 a.m. – 11:45 a.m.

Session 10: Outstanding Early Career Investigator Award Competition
Moderators:
Farah Sheikh, PhD, UC San Diego
Danuta Szczesna-Cordary, PhD, University of Miami Health System

  • Cardiac Reprogramming Inducer ZNF281 Is Indispensable For Heart Development By Interacting With Key Cardiac Transcriptional Factors
    Hisayuki Hashimoto, Keio Universtiy Sch of Med, Tokyo, Japan; Jin Komuro, Keio Univ, Tokyo; Takahiro Nakamura, Keio Universtiy Sch of Med, Tokyo, Japan; Shinsuke Yuasa, Keio Universtiy Sch of Med, Tokyo, Japan, Tokyo, Japan; Keiichi Fukuda, KEIO UNIVERSITY, Tokyo
  • Unbiased Discovery Of Allograft Inflammatory Factor 1 As A New And Critical Immunometabolic Regulatory Node During Cardiac Injury 
    Matthew DeBerge, Edward B Thorp, NORTHWESTERN UNIVERSITY, Chicago, IL
  • ATP-dependent Citrate Lyase Drives Metabolic Remodeling In The Heart During Cancer
    Shijie Liu, Texas Heart Inst, Houston, TX; Seth Gammon, Lin Tan, MD Anderson Cancer Ctr, Houston, TX; Janet Pham, Cedars-Sinai Medical Ctr, Los Angeles, CA; Philip L. Lorenzi, MD Anderson Cancer Ctr, Houston, TX; Heinrich Taegtmeyer, MCGOVERN MEDICAL SCHOOL AT UTHEALTH, Houston, TX; David Piwnica-Worms, MD Anderson Cancer Ctr, Houston, TX; James F Martin, BAYLOR COLLEGE OF MEDICINE, Houston, TX; Anja Karlstaedt, Cedars-Sinai Medical Ctr, Los Angeles, CA
11:45 a.m. – 1:30 p.m. Lunch on Your Own
Or
AHA Center for Accelerated Drug Discovery
1:30 p.m. – 2:45 p.m.

Session 11: Metabolic Cues in Heart Disease
Moderators:
Kedryn Baskin, PhD, Ohio State University
John Elrod, PhD, Temple University

  • Atypical Sphingolipids in Ischemia Mitochondrial Function
    Lauren Cowart, PhD, Virginia Commonwealth University
  • Cardiac metabolism, an important driver of cardiovascular diseases
    Guadalupe Sabio, DVM, PhD, Spanish National Centre for Cardiovascular Research
  • Human cardiac metabolism in health and heart failure
    Zoltan Arany, MD, PhD, University of Pennsylvania
  • Inhibition Of Cardiac Glucose Transporter 1 Suppresses Early Glucose Dependency And Klf5 Activation And Treats Cardiomyopathy In Diabetes
    Sobuj Mia, Univ of Cincinnati, Cincinnati, OH; Ioannis D Kyriazis, Lewis Katz Sch of Med at Temple Univ, Philadelphia, PA; Rafailia Sidiropoulou, Univ of Cincinnati, Cincinnati, OH; Daniel Hill, Athanasios Mantalaris, Wallace H. Coulter Dept of Biomedical Engineering, Georgia Inst of Technology, Atlanta, GA; Konstantinos Drosatos, Univ of Cincinnati, Cincinnati, OH
 
2:45 p.m. – 3:15 p.m. Refreshment Break/Exhibits
3:15 p.m. – 4:30 p.m.

Session 12: Epigenetics and Transcriptional Control of Heart Disease
Moderators:
Manuel Rosa-Garrido, PhD, UCLA
Leslie Leinwand, PhD, University of Colorado

  • Role of antiretroviral drugs in post-translation modification of histone and development of cardiac hypertrophy
    Manish K. Gupta, PhD, University of Central Florida
  • Bmi-1 mediated fibroblast heterogeneity in cardiac wound healing
    Sadia Mohsin, PhD, Temple University
  • Potential role of cardiac DNA methylation in heart failure related to race, diabetes, and ischemia
    Adam Wende, PhD, University of Alabama at Birmingham
  • An Epigenome-wide Association Study Paired With Cell-type-specific Data Identifies Key Regulators Of Heart Failure
    Caitlin Lahue, Brian Gural, Abdalla Alkhawaja, UNC Chapel Hill, Chapel Hill, NC; Douglas Chapski, Manuel Rosa-Garrido, UCLA, Los Angeles, CA; Eleanor Wong, Natl Univ of Singapore, Singapore, Singapore; Wilson Tan, Stanford, Palo Alto, CA; Shuxun Ren, UCLA, Los Angeles, CA; Roger Foo, Cardiovascular Res Inst, Singapore; Thomas M Vondriska II, Yibin Wang, UCLA, Los Angeles, CA; Christoph Rau, UNC Chapel Hill, Chapel Hill, NC
4:30 p.m. – 7:00 p.m. Poster Session 3 (Includes Poster Competition)
7:00 – 9:00 pm Council Dinner

Thursday, July 28

Thursday schedule
TIME (Central Time) ACTIVITY
7:00 a.m. – 8:00 a.m. Continental Breakfast
8:00 a.m. – 9:15 a.m.

Session 13: Cardio-immunology, Inflammation and Cardiac Pathophysiology
Moderators:
Ganesh Halade, PhD, USF
Meena Madhur, MD, PhD, Vanderbilt University

  • Compensatory Cardiomyocyte Growth During Hypertension Requires Resident Cardiac Macrophages
    Slava Epelman, MD, University Health Network
  • Cardiac resident macrophages prevent fibrosis and stimulate angiogenesis
    Xavier Revelo, PhD, University of Minnesota
  • Cardiac Myosin-specific Autoimmune T cells Contribute to Immune Checkpoint Inhibitor-associated Myocarditis
    Daniela Cihakova, MD, PhD, Johns Hopkins University
  • Inflammasome Primed Neutrophils Regulate Myocardial Infarction Induced Myelopoiesis
    Gopalkrishna Sreejit, Sunil Nooti, Western Univ of Health Sci, Pomona, CA; Robert Jaggers, Columbus, OH; Jillian Johnson, Columbus, OH, Columbus, OH; Jianjie Ma, Ohio State Univ Wexner Medical Ctr, Columbus, OH; Andrew Murphy, Baker Heart and Diabetes Inst, Melbourne, Australia; Prabhakara R Nagareddy, The Ohio State Univ, Columbus, OH
9:15 a.m. – 9:45 a.m. Refreshment Break
9:45 a.m. – 11:00 a.m.

Session 14: Interorgan Communications in Heart Disease
Moderators: 
Kristine Deleon-Pennell, PhD, Medical University of South Carolina
Joel Schilling, MD, PhD, Washington University in St Louis

  • Cardiorenal interactions in HFpEF - experimental models and therapeutic findings
    Joshua Hare, MD, University of Miami
  • New mechanisms for BAT to affect the heart
    Kristin Stanford, PhD, Ohio State University
  • Clonal hematopoiesis: hematopoietic clone wars in the cardiovascular system
    Jose Javier Fuster, PhD, Center for Cardiovascular Research
  • Maladaptive Myeloid Lipid Metabolism Promotes Cardiac Diastolic Dysfunction Through Splenic Hematopoiesis
    Mallory Filipp, Zhi-Dong Ge, Northwestern Univ, Chicago, IL; Sanjiv J Shah, Edward B Thorp, NORTHWESTERN UNIVERSITY, Chicago, IL
11:00 a.m. Adjourn

Early Career Keynote Speaker: Ivor Benjamin, MD, FACC, FAHA, Medical College of Wisconsin

Headshot of Ivor Benjamin, MD, FACC, FAHA

Date and Time: July 25, 2022, 11:45 a.m.–12:30 p.m.

Dr. Benjamin received his MD from Johns Hopkins University School of Medicine, internship, and residency in Internal Medicine at Yale University School of Medicine, and received fellowship training in Clinical Cardiology, Molecular Cardiology, and Molecular Biology at the University of Chicago (Michael Reese Hospital), Duke University Medical Center, and University of Texas Southwestern Medical Center in Dallas. As director of the Cardiovascular Center at the Medical College of Wisconsin since 2013 and Professor of Medicine at MCW and Froedtert Hospital, Ivor Benjamin, MD brings more than 25 years of experience leading cardiovascular clinical and research programs. Dr. Benjamin’s leadership of the Cardiovascular Center at the Medical College of Wisconsin is increasing the investigative workforce as Co-Director of an NHLBI T32 training program. Dr. Benjamin is the recipient of numerous medical honors, including the Pioneer Award of the National Institutes of Health and the Dr. Daniel D. Savage Memorial Service Award of the Association of Black Cardiologists.

With more than 30 years of volunteer history with the American Heart Association, he proudly served as President from 2018-2019, and then Immediate Past President from 2019-2020. A highly regarded physician-scientist of molecular cardiovascular remodeling, he was an AHA Established Investigator, a founding member of the Journal of the American Heart Association and currently serves on the editorial boards of Circulation and Circulation Research. As chair of the American Heart Association research committee from 2015-17, he expanded opportunities in research for women, minorities, and undergraduates. Dr. Benjamin is a member of its Board of Directors, Corporate Operations Coordinating Committee, Executive Committee, International Committee and Science & Advisory Coordinating Committee. He is also a longtime member of the association’s Council on Basic Cardiovascular Sciences and Council on Clinical Cardiology.

Keynote Speaker: Leslie Leinwand, PhD, University of Colorado

Leslie Leinwand, PhD, University of Colorado headshotPresentation:  From Bench to Bedside: The Role of Science in Treating a Deadly Disease

Date and Time:  July 26, 2022, 11 a.m.-12 p.m.

Dr. Leslie Leinwand is a Molecular, Cellular, and Developmental Biology (MCDB) Distinguished Professor and the Chief Scientific Officer of the BioFrontiers Institute at the University of Colorado Boulder. She received her Bachelor’s degree from Cornell University and her PhD from Yale University, and completed her post-doctoral training at Rockefeller University. She joined the faculty at Albert Einstein College of Medicine in New York in 1981 and remained there until moving to Colorado in 1995 to be Chair of MCDB. She co-founded Myogen, Inc. which was sold to Gilead Pharmaceuticals. More recently, she was a co-founder of Hiberna, Inc, and of MyoKardia, Inc, a company founded to develop therapeutics for inherited cardiomyopathies. Bristol Myers Squibb acquired MyoKardia in late 2020.

Leslie is a Fellow of the AAAS, former MERIT Awardee of the NIH, Established Investigator of the American Heart Association, elected member of the American Academy of Arts and Sciences and the National Academy of Inventors, and she serves on the International Council for the International Society for Heart Research. She has been honored by the American Heart Association with its Distinguished Scientist Award.

Dr. Leinwand’s research focuses on the genetics and molecular physiology of inherited diseases of the heart and skeletal muscle, and how biological sex modifies heart and skeletal muscle. The study of these diseases has required multidisciplinary approaches, involving biophysics, molecular biology, mouse genetics, cardiac physiology, and the analysis of human tissues.

Target Audience

  • Basic cardiovascular scientists
  • Molecular/cellular biologists
  • Physiologists
  • Translational investigators
  • Clinical trialists
  • Practicing cardiologists
  • Cardiovascular nurses and pharmacists

Learning Objectives

  1. Understand new developments in cardiovascular pathophysiology and their implications for future therapeutics.
  2. Discuss emerging translational research in preventing and treating cardiovascular disease and its precursors.
  3. Recognize the basis of cardio-immunology and the link to cardio-oncology.
  4. Describe about current knowledge about, ongoing research into, and research and clinical gaps around the bidirectional relationship between cardiovascular disease and COVID-19.